A Superior Genetic Engineering Platform

Welcome The Greffex Story

Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy. 

Highlights

  • Founded in 2005 to pursue disruptive and proprietary technology Greffex’s founders first explored in 1998
  • Awarded patents in 2014 for the creation of a fully-deleted, helper-independent adenoviral vector platform
  • Greffex vectors are clean, safe, stable, versatile, and manufactured in a standardized, cost efficient process
  • When applied to vaccines, the universally applicable platform eliminates the need for refrigeration and it can produce doses more quickly, with less lead time, and more cheaply than traditional vaccines
  • NIH-sponsored third-party animal trials demonstrated an impressive 100% protection against a deadly pandemic influenza strain (versus FDA standard of 70% in animals and 40% in humans)
  • Using the target disease’s genetic sequence, Greffex can create any vaccine in 3-4 weeks and produce 100 million doses in 90 days at a fraction of the cost of traditional vaccine production
  • Greffex presently holds 12 patents with 9 additional filings
Patents

Greffex presently holds 12 patents with 9 additional filings

Doses

We can produce 100 million doses in 90 days at a fraction of the cost of traditional vaccine production

The Greffex Platform

Clean

Greffex vectors are deleted of all endogenous vector genes

Safe

Greffex vectors are devoid of contaminating helper or recombinant
replicating viruses

Stable

Greffex vectors are genetically stable and can be stored at room
temperature

Flexible

Greffex vectors can be delivered in different capsids

Versatile

Greffex vectors can be used for different genetic engineering applications

Manufacturing

Greffex vectors are manufactured by a standardized highly efficient
process

Latest News

Our Team

President and Chief Executive Officer

John R. Price

President and Chief Executive Officer
Chief Scientific Officer

Uwe D. Staerz

Chief Scientific Officer
Executive Vice President

William S. Connolly

Executive Vice President